Our top pick for
Building a portfolio
National Research Corporation is a diagnostics & research business based in the US. National Research Corporation shares (NRC) are listed on the NASDAQ and all prices are listed in US Dollars. National Research Corporation employs 485 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$42.30 - $59.85|
|50-day moving average||$48.22|
|200-day moving average||$49.70|
|Wall St. target price||N/A|
|Dividend yield||$0.21 (0.43%)|
|Earnings per share (TTM)||$1.45|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing National Research Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of National Research Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
National Research Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 34x. In other words, National Research Corporation shares trade at around 34x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
National Research Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $49.6 million.
The EBITDA is a measure of a National Research Corporation's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$133.3 million|
|Operating margin TTM||32.16%|
|Gross profit TTM||$84.1 million|
|Return on assets TTM||21.95%|
|Return on equity TTM||76.66%|
|Market capitalisation||$1.2 billion|
TTM: trailing 12 months
There are currently 291,285 National Research Corporation shares held short by investors – that's known as National Research Corporation's "short interest". This figure is 8.8% down from 319,544 last month.
There are a few different ways that this level of interest in shorting National Research Corporation shares can be evaluated.
National Research Corporation's "short interest ratio" (SIR) is the quantity of National Research Corporation shares currently shorted divided by the average quantity of National Research Corporation shares traded daily (recently around 37536.726804124). National Research Corporation's SIR currently stands at 7.76. In other words for every 100,000 National Research Corporation shares traded daily on the market, roughly 7760 shares are currently held short.
However National Research Corporation's short interest can also be evaluated against the total number of National Research Corporation shares, or, against the total number of tradable National Research Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case National Research Corporation's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 National Research Corporation shares in existence, roughly 10 shares are currently held short) or 0.0273% of the tradable shares (for every 100,000 tradable National Research Corporation shares, roughly 27 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against National Research Corporation.
Find out more about how you can short National Research Corporation stock.
Dividend payout ratio: 9.16% of net profits
Recently National Research Corporation has paid out, on average, around 9.16% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), National Research Corporation shareholders could enjoy a 1% return on their shares, in the form of dividend payments. In National Research Corporation's case, that would currently equate to about $0.21 per share.
While National Research Corporation's payout ratio might seem low, this can signify that National Research Corporation is investing more in its future growth.
National Research Corporation's most recent dividend payout was on 26 April 2021. The latest dividend was paid out to all shareholders who bought their shares by 15 April 2021 (the "ex-dividend date").
Over the last 12 months, National Research Corporation's shares have ranged in value from as little as $42.302 up to $59.8472. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while National Research Corporation's is 0.6332. This would suggest that National Research Corporation's shares are less volatile than average (for this exchange).
National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience in the United States and Canada. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, health risk assessments, employee engagement, reputation management, and brand loyalty. The company also offers market insights solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient and resident experience, workforce engagement, health risk assessments, transitions, and improvement tools. Further, the company offers health risk assessment solutions that enable clients to segment populations and manage care for those who are most at risk, engage individuals, enhance preventative care, and manage wellness programs; and transitions solutions, which enable organizations to identify and manage high-risk patients to reduce readmissions, enhance patient satisfaction and support safe care transitions. Additionally, it provides transparency solutions that allow healthcare organizations to share picture of their organization and ensure content informs in consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. The company serves integrated health systems, post-acute providers, and payer organizations.
Everything we know about the Krispy Kreme IPO, plus information on how to buy in.
Everything we know about the Day One Biopharmaceuticals IPO, plus information on how to buy in.
Everything we know about the Enact Holdings IPO, plus information on how to buy in.
Everything we know about the Solid Power IPO, plus information on how to buy in.
Everything we know about the Paymentus Holdings IPO, plus information on how to buy in.
Everything we know about the Qiniu Limited IPO, plus information on how to buy in.
Everything we know about the Qiniu Limited IPO, plus information on how to buy in.
Everything we know about the Ximalaya IPO, plus information on how to buy in.
Everything we know about the Zeta Global Holdings Corp IPO, plus information on how to buy in.
Everything we know about the Paycor HCM IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.